Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

2016290 citationsJournal Articlebronze Open Access

Authors

Toni K. Choueiri

Mayer Fishman · Moffitt Cancer Center

Bernard Escudier · Institut Gustave Roussy

José Luis Perez‐Gracia

Douglas G. McNeel

Brendan D. Curti

Michael R. Harrison

Abstract

Immunomodulatory effects of PD-1 inhibition were demonstrated through multiple lines of evidence across nivolumab doses. Biomarker changes from baseline reflect nivolumab pharmacodynamics in the tumor microenvironment. These data may inform potential combinations. Clin Cancer Res; 22(22); 5461-71. ©2016 AACR.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Renal cell carcinoma treatment CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 22, Issue 22, pp. 5461-5471

DOI: 10.1158/1078-0432.ccr-15-2839

Field-Weighted Citation Impact: 16.39